TPX-100 for knee arthritis: could this peptide change the joint?
Bottom line: TPX-100 is one of the most ambitious peptides being studied for knee arthritis because the goal reaches beyond pain relief. An earlier randomized program reported better knee function, and a later MRI analysis found slower pathological bone-shape change. A new 270-person study is now testing whether that function-plus-structure signal can hold in mild-to-severe knee osteoarthritis.
- What it is
- A 23-amino-acid peptide derived from matrix extracellular phosphoglycoprotein, or MEPE.
- Earlier program
- 118 adults enrolled; 93 formed the principal 200 mg efficacy population and 78 entered the later MRI analysis.
- Signal worth watching
- Better reported function plus less pathological femoral bone-shape change versus the placebo-treated knee.
- Next milestone
- A randomized 270-person Phase 2 study is expected to finish in April 2027.
Why TPX-100 is different from the usual “healing peptide” story
Most online discussions about peptides and painful knees begin with BPC-157, TB-500, or a stack assembled from recovery anecdotes. TPX-100 came through a different door: researchers designed it specifically around bone and cartilage biology, injected it into an arthritic knee, and measured that knee against the participant’s other knee.
That paired-knee design is unusually useful. Age, body weight, activity, genetics, and many other person-to-person differences were naturally shared by both knees. One knee received TPX-100 and the other received saline placebo, while participants, clinicians, sites, and the sponsor remained blinded to the assignment.
What the human data actually show
| Evidence stage | Who was studied | Result worth knowing | How to read it |
|---|---|---|---|
| Earlier Phase 2 program | 118 adults enrolled; median age 60 | Function favored TPX-100 at 6 and 12 months; stair pain also improved | Encouraging patient-reported signal, published as a conference abstract |
| Responder analysis | 93-person 200 mg efficacy group | 61 of 93 treated knees met response criteria at 6 or 12 months | A post hoc analysis using predefined criteria |
| Blinded MRI analysis | 78 participants after image-quality review | Less pathological femoral bone-shape change at 6 and 12 months | A structural signal from a retrospective analysis |
| Current Phase 2 study | 270 adults planned, ages 50–80, with mild-to-severe knee OA | Safety, WOMAC, KOOS pain frequency, and MRI B-score at weeks 27 and 53 | The prospective confirmation test now underway |
The most interesting number is a bone-shape measurement
Osteoarthritis is not simply an empty space where cartilage used to be. The bone beneath the cartilage also remodels, flattening and changing around the joint as disease advances. Researchers can quantify that shift with an MRI-derived femoral “B-score”: movement in the positive direction represents a shape becoming more characteristic of osteoarthritis.
At 12 months, mean B-score change was 0.0856 in TPX-100-treated knees and 0.1969 in placebo-treated knees, a statistically significant difference (P=0.01). At six months, the corresponding changes were 0.0298 and 0.1246 (P=0.02). Lower change was the favorable direction.
A scan is not a life. But a structural measurement becomes far more compelling when it moves beside function rather than instead of it. That is the larger promise here: not merely a quieter knee, but a knee whose mechanics and lived performance may be changing together.
The function signal matters just as much
The main 200 mg efficacy analysis involved 93 participants, with a median age of 60 and median body mass index of 29.2. Conference results reported statistically significant, clinically meaningful advantages for TPX-100-treated knees in daily activities, sports and recreation, knee-related quality of life, and pain on stairs at six and 12 months.
A later responder analysis reported that 61 of 93 treated knees met predefined functional-response criteria at one or both follow-ups. Among the 68 participants who also had tibiofemoral osteoarthritis in both knees, 44 treated knees met the response threshold. These are not vague animal-healing claims; they are human signals tied to activities people want back.
The one boundary that keeps the story honest
The program did not meet its original primary MRI goal: patellofemoral cartilage thickness was not significantly different between treated and placebo knees. The later bone-shape and responder findings were retrospective or post hoc, and much of the published work involved sponsor-affiliated researchers. That makes TPX-100 a serious hypothesis with human support—not a settled answer.
Could TPX-100 matter for a “bone-on-bone” knee?
Possibly, and the next study is substantially more relevant to that question. The earlier trial selected people with grade 2–3 patellofemoral cartilage defects, although many participants also had more advanced tibiofemoral damage. The current study deliberately includes mild-to-severe tibiofemoral osteoarthritis in adults ages 50–80.
That does not establish that TPX-100 can rebuild an end-stage joint or remove the need for knee replacement. It does create a credible test: if participants with more severe disease improve on WOMAC function and pain while MRI B-score moves in the same direction, the conversation changes. The field would have evidence that a short peptide intervention may influence both the experience and trajectory of knee osteoarthritis.
The 270-person trial is the result to watch
The active Phase 2 study compares TPX-100 with phosphate-buffered saline placebo after four weekly knee injections. Its primary registered outcome tracks toxicity through weeks 27 and 53. Secondary outcomes measure WOMAC pain and physical function, KOOS pain frequency, and MRI-based femoral B-score.
ClinicalTrials.gov lists the study as active but no longer recruiting, with estimated primary completion on March 25, 2027 and full completion on April 15, 2027. Those dates can move, but the design tells us exactly what matters next.
What would change our view: a convincing improvement in pain and function at weeks 27 and 53, a matching shift in B-score, a meaningful result among people with more severe disease, and a full publication that lets independent researchers inspect the analysis and safety data.
Community radar: people are asking a bigger question
Across knee and peptide communities, people rarely ask only whether a product can lower pain for a few weeks. They ask whether they can keep skiing, climbing stairs, training, or caring for family—and whether “stable” damage can become genuine progress. Community reports cannot answer those questions, but they reveal the outcomes research should measure.
TPX-100 is compelling because its current study is aimed at that wider scorecard. Pain, function, bone shape, time, and disease severity all belong in the answer.
Questions to take to a knee specialist
- Which part of the knee is damaged, and how severe is it?
- Is the near-term goal less pain, better function, slower structural progression, or all three?
- Which measurements would show that the joint is stable or changing over time?
- Would the result of an emerging-treatment trial apply to this exact pattern of osteoarthritis?
- What finding would change the timing of a knee-replacement decision?
Research and community sources
- McGuire D, et al. TPX-100, pathological bone-shape change, and cartilage stability. Arthritis Research & Therapy, 2021. PMID 34535197.
- ClinicalTrials.gov NCT01925261: completed randomized Phase 2 TPX-100 knee study.
- ClinicalTrials.gov NCT06865079: current 270-person Phase 2 knee-osteoarthritis study.
- 2017 ACR abstract: knee function after intra-articular TPX-100.
- 2018 ACR abstract: functional responders and tibiofemoral cartilage.
- GLP-1 Forum community discussion: meniscus damage, osteoarthritis, activity, and progression. Used for question discovery, not treatment evidence.
- MESO-Rx community discussion: recovery peptides and activity-related joint pain. Used for question discovery, not treatment evidence.
Published and evidence reviewed August 23, 2026. This is an evidence summary, not a diagnosis or treatment recommendation. Trial status and completion dates can change. Report a correction or new result.